Keywords: شاخص شدت بیماری پسوریازیس; 4PL; 4 parameters logistic regression; DEGs; Differentially expressed genes; ELISA; Enzyme-linked immunosorbent assays; FC; Fold change; GEO; Gene Expression Omnibus; LC/GC-MS; Liquid chromatography/Gas chromatography-mass spectrometry; PASI; Psoriasi
مقالات ISI شاخص شدت بیماری پسوریازیس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: شاخص شدت بیماری پسوریازیس; 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
Keywords: شاخص شدت بیماری پسوریازیس; diet; fish oil; nutrition; omega-3; oral vitamin D; psoriasis; selenium; vitamin B12; 1,25-dihydroxycholecalciferol; 1,25-dihydroxyvitamin D3; 1,25-(OH)2D3; DHA; docosahexaenoic acid; EPA; eicosapentaenoic acid; PASI; Psoriasis Area Severity Index; UV; ul
Microbe-Dependent Induction of IL-9 by CLA+ T Cells in Psoriasis and Relationship with IL-17A
Keywords: شاخص شدت بیماری پسوریازیس; ASO; anti-streptolysin O; CA; Candida albicans; CLA; cutaneous lymphocyte-associated antigen; CLA-/Epi; co-cultures of CLA- T cells and autologous epidermal cells; CLA+/Epi; co-cultures of CLA+ T cells and autologous epidermal cells; DC; dendritic cel
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Keywords: شاخص شدت بیماری پسوریازیس; biologic therapy; effectiveness; psoriasis; real-world; registry; safety; systemic therapy; BSA; body surface area; BMI; body mass index; DLQI; Dermatology Life Quality Index; EQ-5D; Euro-QoL-5 Dimensional; EQ-5D-3L; Euro-QoL-5 Dimensional-3 Level; IGA; I
Formula PSORI-CM01 inhibits the inflammatory cytokine and chemokine release in keratinocytes via NF-κB expression
Keywords: شاخص شدت بیماری پسوریازیس; PSORI-CM01; formula PSORI-CM01; PCM01CS; serum contained PSORI-CM01; IMQ; imiquimod; PASI; Psoriasis Area Severity Index; IFN-γ; interferon-γ; HE; Hematoxylin and eosin; IL-6; interleukin 6; IL-8; interleukin 8; IL-12; interleukin 12; IL-17; interleukin
Investigating the potential of Oxymatrine as a psoriasis therapy
Keywords: شاخص شدت بیماری پسوریازیس; Psoriasis; Oxymatrine; Hyperproliferation; Keratinocytes; OMT; Oxymatrine; HK; human skin keratinocytes; UVB; Ultraviolet B; PASI; Psoriasis Area Severity Index; SFM; serum-free media; FG; Full Green's medium; BrdU; Bromodeoxyuridine; 3-D; three-dimension
TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study
Keywords: شاخص شدت بیماری پسوریازیس; 18FDG; 18-fluoro-2-deoxy-d-glucose; hs-CRP; high-sensitivity C-reactive protein; PASI; Psoriasis Area Severity Index; PET/CT; position emission tomography-computed tomography; TBR; target-to-background ratio; TNF-α; tumor necrosis factor alpha;
Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2
Keywords: شاخص شدت بیماری پسوریازیس; ACKR2; atypical chemokine receptor 2; IMQ; imiquimod; PASI; Psoriasis Area Severity Index; WT; wild type;
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Keywords: شاخص شدت بیماری پسوریازیس; BIOBADADERM; Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases; CI; confidence interval; PASI; Psoriasis Area Severity Index; RR; risk ratio; TNF; tumor necrosis factor;
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry
Keywords: شاخص شدت بیماری پسوریازیس; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; PASI; Psoriasis Area Severity Index; PASI 75; 75% improvement in the Psoriasis Area Severity Index score; TNF; tumor necrosis